EGFR and glioblastoma: The first study that reported the use of mRNA as biomarkers was by Skog et al., where Glioblastoma patients displayed elevated EGFRvIII mRNA, a mutant version of EGFR, in the microvesicles of their sera samples in approximately 28% of the patients.